Timothy Voorhees
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders (NCT06672705) | Timothy Voorhees | 2025-06-16 |
| Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder (NCT05786040) | Timothy Voorhees | 2023-03-23 |
| Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma (NCT05665725) | Timothy Voorhees | 2023-01-31 |
Track Timothy Voorhees automatically
Every clearance here is in the API, with alerts when new ones post.